These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 10720131)
1. Interferon alfa as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single center. Kloke O; Opalka B; Niederle N Leukemia; 2000 Mar; 14(3):389-92. PubMed ID: 10720131 [TBL] [Abstract][Full Text] [Related]
2. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189 [TBL] [Abstract][Full Text] [Related]
5. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Higano CS; Chielens D; Raskind W; Bryant E; Flowers ME; Radich J; Clift R; Appelbaum F Blood; 1997 Oct; 90(7):2549-54. PubMed ID: 9326220 [TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies. Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190 [TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center. Kantarjian HM; Talpaz M Leuk Lymphoma; 1993; 11 Suppl 1():169-74. PubMed ID: 8251891 [No Abstract] [Full Text] [Related]
8. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025 [TBL] [Abstract][Full Text] [Related]
9. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia. Itoh T; Tamura S; Takemoto Y; Kakishita E Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680 [TBL] [Abstract][Full Text] [Related]
10. Long-term follow-Up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood; 1998 Sep; 92(5):1541-8. PubMed ID: 9716581 [TBL] [Abstract][Full Text] [Related]
11. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. Mahon FX; Delbrel X; Cony-Makhoul P; Fabères C; Boiron JM; Barthe C; Bilhou-Nabéra C; Pigneux A; Marit G; Reiffers J J Clin Oncol; 2002 Jan; 20(1):214-20. PubMed ID: 11773172 [TBL] [Abstract][Full Text] [Related]
12. Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results. Alimena G; Meloni G; de Cuia MR; Rondinelli MB; Lo Coco F; Montefusco E; Mancini M; Pinto R; Nanni M; Cedrone M Leuk Lymphoma; 1993; 11 Suppl 1():281-91. PubMed ID: 7902746 [TBL] [Abstract][Full Text] [Related]
13. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376 [TBL] [Abstract][Full Text] [Related]
14. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Cortes J; Kantarjian H; O'Brien S; Robertson LE; Pierce S; Talpaz M Am J Med; 1996 Apr; 100(4):452-5. PubMed ID: 8610733 [TBL] [Abstract][Full Text] [Related]
16. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia]. Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778 [TBL] [Abstract][Full Text] [Related]
17. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML. Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157 [TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H; Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239 [TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Farag SS; Ruppert AS; Mrózek K; Carroll AJ; Pettenati MJ; Le Beau MM; Peterson BL; Powell BL; Ozer H; Silver RT; Larson RA; Bloomfield CD; Int J Oncol; 2004 Jul; 25(1):143-51. PubMed ID: 15201999 [TBL] [Abstract][Full Text] [Related]
20. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]